Published in J Virol on November 01, 2003
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol (2006) 1.82
Resistance to integrase inhibitors. Viruses (2010) 1.75
Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology (2008) 1.48
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 1.41
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol (2009) 1.30
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol (2012) 1.28
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol (2008) 1.27
LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog (2012) 1.25
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother (2013) 1.17
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc Natl Acad Sci U S A (2006) 1.16
Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J Biol Chem (2005) 1.13
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother (2008) 1.10
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (2008) 1.05
Defining the DNA substrate binding sites on HIV-1 integrase. J Mol Biol (2008) 1.01
A dynamic model of HIV integrase inhibition and drug resistance. J Mol Biol (2010) 0.99
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem (2008) 0.98
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother (2005) 0.97
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
Recent progress in antiretrovirals--lessons from resistance. Drug Discov Today (2008) 0.92
HIV resistance to raltegravir. Eur J Med Res (2009) 0.89
Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J Virol (2006) 0.84
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother (2008) 0.84
HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients. Virol J (2011) 0.80
Role of raltegravir in the management of HIV-1 infection. HIV AIDS (Auckl) (2011) 0.77
A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid. Biophys J (2007) 0.76
Mechanistic and pharmacological analyses of HIV-1 integration. Methods (2009) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci U S A (1990) 6.85
Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci U S A (1991) 6.58
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science (1992) 4.97
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
HIV chemotherapy. Nature (2001) 3.63
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A (2000) 3.26
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol (1986) 2.40
Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol (1993) 2.22
Repair of gaps in retroviral DNA integration intermediates. J Virol (2000) 2.00
Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem (1995) 1.85
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs (2003) 1.31
Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol (1998) 1.25
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol (2000) 1.17
Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol (1998) 1.15
Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol (1997) 1.15
Inhibitors of human immunodeficiency virus integrase. Adv Virus Res (1999) 1.13
New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol (2002) 1.13
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11
The dead-end elimination theorem: mathematical aspects, implementation, optimizations, evaluation, and performance. Methods Mol Biol (2000) 1.10
Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol (1996) 1.07
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother (2002) 1.01
Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology (2003) 0.99
Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol Biol (2001) 0.94
In search of authentic inhibitors of HIV-1 integration. Antivir Chem Chemother (2002) 0.92
Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Devel (2001) 0.92
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2002) 4.91
LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem (2003) 3.97
Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur J Med Chem (2006) 3.79
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther (2007) 2.64
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther (2010) 2.51
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol (2010) 2.48
Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Farmaco (2002) 2.47
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem (2005) 2.44
Transportin-SR2 imports HIV into the nucleus. Curr Biol (2008) 2.35
The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J Biol Chem (2005) 2.28
Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev (2005) 2.24
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother (2005) 2.14
Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol (2006) 2.09
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem (2006) 2.04
Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco (2002) 2.04
Long-term reversal of diabetes in non-obese diabetic mice by liver-directed gene therapy. J Gene Med (2013) 2.02
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties. Bioorg Med Chem Lett (2003) 1.97
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem (2007) 1.89
Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol (2006) 1.82
A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol (2002) 1.78
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
Fluorescence lifetime standards for time and frequency domain fluorescence spectroscopy. Anal Chem (2007) 1.74
LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther (2010) 1.72
Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem (2009) 1.71
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol (2010) 1.70
Cellular co-factors of HIV-1 integration. Trends Biochem Sci (2006) 1.68
Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem (2006) 1.68
Rational design of photoconvertible and biphotochromic fluorescent proteins for advanced microscopy applications. Chem Biol (2011) 1.64
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem (2009) 1.64
In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol (2003) 1.63
Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol (2003) 1.61
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother (2004) 1.60
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur J Med Chem (2007) 1.60
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 1.59
Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. Molecules (2007) 1.55
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (2004) 1.55
Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther (2009) 1.54
Clinical features and treatment of adenovirus infections. Rev Med Virol (2008) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Dark states in monomeric red fluorescent proteins studied by fluorescence correlation and single molecule spectroscopy. Biophys J (2008) 1.52
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem (2002) 1.51
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
Stretched exponential decay and correlations in the catalytic activity of fluctuating single lipase molecules. Proc Natl Acad Sci U S A (2005) 1.51
Selective inhibitors of picornavirus replication. Med Res Rev (2008) 1.50
Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther (2002) 1.50
Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75. J Biol Chem (2004) 1.47
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
Antiviral therapy: quo vadis? Future Med Chem (2010) 1.44
Comparison of lentiviral vector titration methods. BMC Biotechnol (2006) 1.42
Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem (2004) 1.41
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 1.41
Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother (2012) 1.40
Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med (2005) 1.38
Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules (2006) 1.36
Correct diffusion coefficients of proteins in fluorescence correlation spectroscopy. Application to tubulin oligomers induced by Mg2+ and Paclitaxel. Biophys J (2004) 1.36
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur J Med Chem (2008) 1.36
Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders. J Med Chem (2004) 1.35
Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res (2007) 1.33
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
Human immunoglobulin adsorption investigated by means of quartz crystal microbalance dissipation, atomic force microscopy, surface acoustic wave, and surface plasmon resonance techniques. Langmuir (2004) 1.32
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of PogZ. J Biol Chem (2009) 1.30
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc (2008) 1.29